BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 16394042)

  • 1. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
    Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
    Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
    Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
    Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.
    Zola P; Fuso L; Mazzola S; Piovano E; Perotto S; Gadducci A; Galletto L; Landoni F; Maggino T; Raspagliesi F; Sartori E; Scambia G
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S150-4. PubMed ID: 17868785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
    Orr JM; Barnett JC; Leath CA
    Gynecol Oncol; 2011 Sep; 122(3):501-4. PubMed ID: 21714992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
    Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
    J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttherapy surveillance of women with cervical cancer: an outcomes analysis.
    Bodurka-Bevers D; Morris M; Eifel PJ; Levenback C; Bevers MW; Lucas KR; Wharton JT
    Gynecol Oncol; 2000 Aug; 78(2):187-93. PubMed ID: 10926801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
    Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
    J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of routine follow-up in patients with recurrent uterine cancer.
    Smith CJ; Heeren M; Nicklin JL; Perrin LC; Land R; Crandon AJ; Obermair A
    Gynecol Oncol; 2007 Oct; 107(1):124-9. PubMed ID: 17655917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence patterns and surveillance for patients with early stage endometrial cancer.
    Salani R; Nagel CI; Drennen E; Bristow RE
    Gynecol Oncol; 2011 Nov; 123(2):205-7. PubMed ID: 21820709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for recurrence of vaginal intraepithelial neoplasia in the vaginal vault after laser vaporization.
    Kim HS; Park NH; Park IA; Park JH; Chung HH; Kim JW; Song YS; Kang SB
    Lasers Surg Med; 2009 Mar; 41(3):196-202. PubMed ID: 19291750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and benefits of routine follow-up after curative treatment for endometrial cancer.
    Agboola OO; Grunfeld E; Coyle D; Perry GA
    CMAJ; 1997 Oct; 157(7):879-86. PubMed ID: 9327795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors.
    Ben Arie A; Lavie O; Gdalevich M; Voldarsky M; Barak F; Schneider D; Levy T; Anteby E; Gemer O
    Eur J Surg Oncol; 2012 Feb; 38(2):166-9. PubMed ID: 22056646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme.
    Reddoch JM; Burke TW; Morris M; Tornos C; Levenback C; Gershenson DM
    Gynecol Oncol; 1995 Nov; 59(2):221-5. PubMed ID: 7590477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients.
    Rulyak SJ; Lieberman DA; Wagner EH; Mandelson MT
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):470-6; quiz 407. PubMed ID: 17270502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
    Howell LP; Gurusinghe S; Tabnak F; Sciortino S
    Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for gynecologic cancer. Vulvar, vaginal, endometrial, and ovarian neoplasms.
    Hall KL; Dewar MA; Perchalski J
    Prim Care; 1992 Sep; 19(3):607-20. PubMed ID: 1410066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
    Nygård M; Daltveit AK; Thoresen SO; Nygård JF
    BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal cancer after hysterectomy for benign disease: value of cytologic screening.
    Bell J; Sevin BU; Averette H; Nadji M
    Obstet Gynecol; 1984 Nov; 64(5):699-702. PubMed ID: 6493662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
    Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
    Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.